BeiGene, Ltd. (BEIGF)

Market Cap	18.75B
Revenue (ttm)	3.35B
Net Income (ttm)	-854.42M
Shares Out	n/a
EPS (ttm)	-8.19
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Open	14.40
Previous Close	n/a
Day's Range	14.40 - 14.40
52-Week Range	11.00 - 16.58
Beta	0.62
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 25, 2025

About BeiGene

BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. Its commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 10,600
• Stock Exchange: OTCMKTS
• Ticker Symbol: BEIGF

Financial Performance

In 2023, BeiGene's revenue was 2.46 billion, an increase of 73.65% compared to the previous year's 1.42 billion. Losses were -881.71 million, -56.00% less than in 2022.

Financial numbers in CNY